Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
According to the latest research, the global PSMA PET Imaging and Treatment market size was valued at USD 508.79 million in 2022 and is expected to expand at a CAGR of 33.47% during the forecast period, reaching USD 2876.7 million by 2028.
Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is expressed in high levels in prostate cancer cells. Due to its location on the cell surface, PSMA is a popular target for imaging to identify the presence of prostate cancer and to deliver drugs directly to the cancerous cells. PSMA PET Imaging mainly refers to a new imaging technology of prostate cancer that can locate cancer lesions. Currently, PSMA PET uses FDA-approved PET-sensitive drugs. PSMA PET Imaging and Treatment involves diagnosing prostate cancer, improving symptoms, and reducing tumor size.
Influence of COVID-19 Outbreak on PSMA PET Imaging and Treatment Industry Development
The raging COVID-19 has plunged the global economic environment into depression. The impact of COVID-19 on the PSMA PET Imaging and Treatment industry will involve all major links and all entities of the industry chain. In the short term, the outbreak of the epidemic has prompted countries around the world to implement comprehensive traffic control and other measures. This poses a certain threat to the PSMA PET Imaging and Treatment supply chain. This is mainly reflected in the impact of the epidemic on the procurement of raw materials in the PSMA PET Imaging and Treatment industry. Due to the limited production and poor logistics of raw material suppliers, the procurement of raw materials is facing difficulties, but with the progress of the resumption of work and production, this situation will be effectively alleviated.
From the perspective of PSMA PET Imaging and Treatment enterprises, the main reason is to increase cost pressure. The outbreak of COVID-19 has put companies under pressure from tight cash flow, supply chain disruption, and a general decline in market supply and demand. Most companies expect a sharp drop in revenue. Employee wages, loan repayments and rental expenses are the main cost pressures for business operations. Especially for SMEs, paying staff wages has become the biggest cost pressure. In contrast, workers in large companies are under relatively less wage pressure.
From the downstream point of view, the impact of the epidemic on the downstream customers of PSMA PET Imaging and Treatment is comprehensive. The COVID-19 pandemic has impacted healthcare delivery globally since December 2019. The COVID-19 pandemic has impacted prostate cancer diagnosis and has led to delays in drug treatment for prostate cancer. At the same time, the pandemic has negatively impacted both new diagnoses and surveillance of previously treated prostate cancer. With the increase in vaccination rates in various places and the gradual control of the epidemic, the diagnosis and treatment of prostate cancer patients will gradually resume. Therefore, in the later period of the epidemic, the demand for PSMA PET Imaging and Treatment will continue to rise.
Advantages of PSMA PET Imaging over conventional imaging techniques
In the diagnostic part of prostate cancer, PSMA PET Imaging has obvious advantages. First, PSMA-binding analogs have high potential as highly sensitive and reasonably specific molecular tracers, possessing most of the imaging features required for various treatment decisions in prostate malignancies. Second, PSMA PET scans are more accurate. In March 2020, the Lancet published an article showing that a medical imaging technique called PSMA PET/CT can provide levels of prostate cancer-related molecules as well as detailed systemic distribution, which can help doctors determine how far the disease has spread. This method was nearly one-third more accurate in pinpointing the spread of prostate cancer in the body than existing standard imaging methods: PSMA PET/CT was 92 percent accurate, compared to 65 percent for standard imaging. %. It can be seen that PSMA PET imaging has obvious advantages in accurately locating the spread of prostate cancer. Finally, although both PSMA PET Imaging and conventional imaging methods have radiation, the radiation dose for PSMA PET is less than half that of conventional imaging. Therefore, due to the advantages of high accuracy and low radiation, PSMA PET Imaging has become an important method for the diagnosis of prostate cancer.
Growing geriatric population is driving market growth
For PSMA PET Imaging and Treatment, the growing geriatric population is driving the market growth. The risk of prostate cancer increases with age, especially after age 50, according to the American Society of Clinical Oncology. About 60% of prostate cancers are diagnosed in people 65 or older. Older adults diagnosed with prostate cancer may face unique challenges, especially when it comes to cancer treatment. Currently, the global population is aging, and the proportion of the elderly population to the total population is growing in every country. According to the recent World Population Prospects report released by the United Nations, by 2050, one in six people in the world will be over the age of 65 (16%). The number of people aged 80 or over is expected to triple from 143 million in 2019 to 426 million in 2050. At present, the regions with more serious population aging are in Asia and Europe. The risk of prostate cancer in older adults continues to rise as they age. Therefore, the increasing aging population will promote the demand for PSMA PET Imaging and Treatment to a certain extent.
Region Overview:
United States dominated the PSMA PET Imaging and Treatment market in 2022, with a market share of 77.65%.
Company Overview:
Lantheus, Telix, Novartis were the top 3 players in the PSMA PET Imaging and Treatment market in 2022, taking up a market share of 100% together.
Lantheus
Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease.
Telix
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic ('theranostic') radiopharmaceuticals.
Segmentation Overview:
Among different product types, Acinar Adenocarcinoma segment is anticipated to contribute the largest market share in 2028.
Acinar Adenocarcinoma
This cancer accounts for virtually all prostatic adenocarcinomas. Acini cells line the prostate’s fluid-secreting glands. The cancer starts growing in the back (periphery) of the prostate near the rectum and may be felt during a doctor’s digital rectal exam.
Ductal Adenocarcinoma
This cancer is a rarer but more aggressive form of adenocarcinoma. It develops in the cells lining the tubes and ducts of the prostate gland. When it occurs, it frequently develops along with acinar adenocarcinoma.
Application Overview:
By application, the Hospitals segment occupied the biggest share from 2018 to 2022.
This report elaborates on the market size, market characteristics, and market growth of the PSMA PET Imaging and Treatment industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of PSMA PET Imaging and Treatment. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global PSMA PET Imaging and Treatment Market Report Include:
Market Size Estimates: PSMA PET Imaging and Treatment market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: PSMA PET Imaging and Treatment market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the PSMA PET Imaging and Treatment market
Segment Market Analysis: PSMA PET Imaging and Treatment market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: PSMA PET Imaging and Treatment market situations and prospects in major and top regions and countries
PSMA PET Imaging and Treatment Market
PSMA PET Imaging and Treatment Industry Chain: PSMA PET Imaging and Treatment market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
PSMA PET Imaging and Treatment Industry News, Policies by regions
PSMA PET Imaging and Treatment Industry Porters Five Forces Analysis
Key players in the global PSMA PET Imaging and Treatment market are covered in Chapter 2:
Telix
Novartis
Blue Earth Diagnostics, Inc
Clarity
Lantheus
RadioMedix
In Chapter 6 and Chapter 9, on the basis of types, the PSMA PET Imaging and Treatment market from 2018 to 2028 is primarily split into:
Acinar Adenocarcinoma
Ductal Adenocarcinoma
Others
In Chapter 7 and Chapter 10, on the basis of applications, the PSMA PET Imaging and Treatment market from 2018 to 2028 covers:
Hospitals
Diagnostic Centers
Academic Research Institutions
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global PSMA PET Imaging and Treatment market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the PSMA PET Imaging and Treatment industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of PSMA PET Imaging and Treatment market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the PSMA PET Imaging and Treatment industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on PSMA PET Imaging and Treatment market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the PSMA PET Imaging and Treatment market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed PSMA PET Imaging and Treatment market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
2022
Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is expressed in high levels in prostate cancer cells. Due to its location on the cell surface, PSMA is a popular target for imaging to identify the presence of prostate cancer and to deliver drugs directly to the cancerous cells. PSMA PET Imaging mainly refers to a new imaging technology of prostate cancer that can locate cancer lesions. Currently, PSMA PET uses FDA-approved PET-sensitive drugs. PSMA PET Imaging and Treatment involves diagnosing prostate cancer, improving symptoms, and reducing tumor size.
Influence of COVID-19 Outbreak on PSMA PET Imaging and Treatment Industry Development
The raging COVID-19 has plunged the global economic environment into depression. The impact of COVID-19 on the PSMA PET Imaging and Treatment industry will involve all major links and all entities of the industry chain. In the short term, the outbreak of the epidemic has prompted countries around the world to implement comprehensive traffic control and other measures. This poses a certain threat to the PSMA PET Imaging and Treatment supply chain. This is mainly reflected in the impact of the epidemic on the procurement of raw materials in the PSMA PET Imaging and Treatment industry. Due to the limited production and poor logistics of raw material suppliers, the procurement of raw materials is facing difficulties, but with the progress of the resumption of work and production, this situation will be effectively alleviated.
From the perspective of PSMA PET Imaging and Treatment enterprises, the main reason is to increase cost pressure. The outbreak of COVID-19 has put companies under pressure from tight cash flow, supply chain disruption, and a general decline in market supply and demand. Most companies expect a sharp drop in revenue. Employee wages, loan repayments and rental expenses are the main cost pressures for business operations. Especially for SMEs, paying staff wages has become the biggest cost pressure. In contrast, workers in large companies are under relatively less wage pressure.
From the downstream point of view, the impact of the epidemic on the downstream customers of PSMA PET Imaging and Treatment is comprehensive. The COVID-19 pandemic has impacted healthcare delivery globally since December 2019. The COVID-19 pandemic has impacted prostate cancer diagnosis and has led to delays in drug treatment for prostate cancer. At the same time, the pandemic has negatively impacted both new diagnoses and surveillance of previously treated prostate cancer. With the increase in vaccination rates in various places and the gradual control of the epidemic, the diagnosis and treatment of prostate cancer patients will gradually resume. Therefore, in the later period of the epidemic, the demand for PSMA PET Imaging and Treatment will continue to rise.
Advantages of PSMA PET Imaging over conventional imaging techniques
In the diagnostic part of prostate cancer, PSMA PET Imaging has obvious advantages. First, PSMA-binding analogs have high potential as highly sensitive and reasonably specific molecular tracers, possessing most of the imaging features required for various treatment decisions in prostate malignancies. Second, PSMA PET scans are more accurate. In March 2020, the Lancet published an article showing that a medical imaging technique called PSMA PET/CT can provide levels of prostate cancer-related molecules as well as detailed systemic distribution, which can help doctors determine how far the disease has spread. This method was nearly one-third more accurate in pinpointing the spread of prostate cancer in the body than existing standard imaging methods: PSMA PET/CT was 92 percent accurate, compared to 65 percent for standard imaging. %. It can be seen that PSMA PET imaging has obvious advantages in accurately locating the spread of prostate cancer. Finally, although both PSMA PET Imaging and conventional imaging methods have radiation, the radiation dose for PSMA PET is less than half that of conventional imaging. Therefore, due to the advantages of high accuracy and low radiation, PSMA PET Imaging has become an important method for the diagnosis of prostate cancer.
Growing geriatric population is driving market growth
For PSMA PET Imaging and Treatment, the growing geriatric population is driving the market growth. The risk of prostate cancer increases with age, especially after age 50, according to the American Society of Clinical Oncology. About 60% of prostate cancers are diagnosed in people 65 or older. Older adults diagnosed with prostate cancer may face unique challenges, especially when it comes to cancer treatment. Currently, the global population is aging, and the proportion of the elderly population to the total population is growing in every country. According to the recent World Population Prospects report released by the United Nations, by 2050, one in six people in the world will be over the age of 65 (16%). The number of people aged 80 or over is expected to triple from 143 million in 2019 to 426 million in 2050. At present, the regions with more serious population aging are in Asia and Europe. The risk of prostate cancer in older adults continues to rise as they age. Therefore, the increasing aging population will promote the demand for PSMA PET Imaging and Treatment to a certain extent.
Region Overview:
United States dominated the PSMA PET Imaging and Treatment market in 2022, with a market share of 77.65%.
Company Overview:
Lantheus, Telix, Novartis were the top 3 players in the PSMA PET Imaging and Treatment market in 2022, taking up a market share of 100% together.
Lantheus
Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease.
Telix
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic ('theranostic') radiopharmaceuticals.
Segmentation Overview:
Among different product types, Acinar Adenocarcinoma segment is anticipated to contribute the largest market share in 2028.
Acinar Adenocarcinoma
This cancer accounts for virtually all prostatic adenocarcinomas. Acini cells line the prostate’s fluid-secreting glands. The cancer starts growing in the back (periphery) of the prostate near the rectum and may be felt during a doctor’s digital rectal exam.
Ductal Adenocarcinoma
This cancer is a rarer but more aggressive form of adenocarcinoma. It develops in the cells lining the tubes and ducts of the prostate gland. When it occurs, it frequently develops along with acinar adenocarcinoma.
Application Overview:
By application, the Hospitals segment occupied the biggest share from 2018 to 2022.
This report elaborates on the market size, market characteristics, and market growth of the PSMA PET Imaging and Treatment industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of PSMA PET Imaging and Treatment. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global PSMA PET Imaging and Treatment Market Report Include:
Market Size Estimates: PSMA PET Imaging and Treatment market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: PSMA PET Imaging and Treatment market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the PSMA PET Imaging and Treatment market
Segment Market Analysis: PSMA PET Imaging and Treatment market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: PSMA PET Imaging and Treatment market situations and prospects in major and top regions and countries
PSMA PET Imaging and Treatment Market
Competitive Landscape
and Major Players: Analysis of 10-15 leading market players, sales, price, revenue, gross, gross margin, product/service profile and recent development/updates, etc.PSMA PET Imaging and Treatment Industry Chain: PSMA PET Imaging and Treatment market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
PSMA PET Imaging and Treatment Industry News, Policies by regions
PSMA PET Imaging and Treatment Industry Porters Five Forces Analysis
Key players in the global PSMA PET Imaging and Treatment market are covered in Chapter 2:
Telix
Novartis
Blue Earth Diagnostics, Inc
Clarity
Lantheus
RadioMedix
In Chapter 6 and Chapter 9, on the basis of types, the PSMA PET Imaging and Treatment market from 2018 to 2028 is primarily split into:
Acinar Adenocarcinoma
Ductal Adenocarcinoma
Others
In Chapter 7 and Chapter 10, on the basis of applications, the PSMA PET Imaging and Treatment market from 2018 to 2028 covers:
Hospitals
Diagnostic Centers
Academic Research Institutions
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global PSMA PET Imaging and Treatment market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the PSMA PET Imaging and Treatment industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of PSMA PET Imaging and Treatment market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the PSMA PET Imaging and Treatment industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on PSMA PET Imaging and Treatment market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the PSMA PET Imaging and Treatment market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed PSMA PET Imaging and Treatment market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
Years considered for this report:
Historical Years:
2018-2022Base Year:
2022Estimated Year:
2023Forecast Period:
2023-2028Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
